Reach-hfpef trial
WebRehabilitation Enablement in Chronic Heart Failure – a facilitated self-care rehabilitation intervention in patients with heart failure with preserved ejection fraction (REACH-HFpEF) and their caregivers: rationale and protocol for a single-centre pilot randomised controlled trial. BMJ Open, 2016. Read the full rationale and protocol here. 2015 WebResults Compared to the REACH-HF multicentre trial, patients treated at the Beacon Site were more likely to be female (33.8% vs 22.9%), older (75.6 vs 70.1), had a more severe classification of ...
Reach-hfpef trial
Did you know?
WebJan 1, 2024 · A. A. A. Heart failure with preserved ejection fraction (HFpEF) has been called the greatest unmet need in cardiovascular medicine. About 6.2 million Americans and more than 23 million individuals worldwide have HF, with about half of them having HFpEF. 1 Estimates suggest that by 2030 the prevalence of HF will increase by 46% and total … National Center for Biotechnology Information
WebStrengths and limitations of this study. Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF) is the first comprehensive home-based, self-management cardiac … WebAug 7, 2024 · This is an international, multicentre, parallel-group, event-driven, randomised, double-blind study in patients with HFpEF, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death and …
WebThe REACH-HFpEF Trial Research type Research Study Full title Randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with … WebFeb 1, 2024 · Our REACH-HF intervention offers a new evidence-based cardiac rehabilitation option that could increase uptake of cardiac rehabilitation in patients with heart failure not …
WebNov 10, 2024 · Study aims to REACH out to heart failure patients. The Universities of Dundee, Glasgow, Exeter, Birmingham, Cambridge, and York have received £2.4 million to …
WebSep 3, 2024 · Background Reach Out is a factorial trial studying multicomponent behavioral interventions to reduce blood pressure in hypertensive emergency department patients. The original study protocol was ... phil n great hvacWebAug 27, 2024 · Heading into the European Society of Cardiology (ESC) Congress 2024, all eyes appeared to be on empagliflozin as cardiologists and other clinicians awaited the results of the EMPEROR-Preserved trial, which Eli Lilly and Company and Boehringer Ingelheim announced as the first and only successful trial for heart failure with preserved … phil nice actorWebApr 9, 2024 · In uncertain cases, i.e. in patients with a high pre-test probability, exercise intolerance and inconclusive results, an invasive study might be recommended. 15, 20 … ts employee form 16WebMay 17, 2024 · VITALITY-HFpEF is a placebo-controlled, double-blind, multi-center, phase IIb trial of ≈735 patients, ≥45 years with HFpEF and ejection fraction ≥45% who will be randomized 1:1:1 to placebo, 10 mg, or 15 mg vericiguat. The primary end point is change in Kansas City Cardiomyopathy Questionnaire physical limitation score from baseline to ... tse mode installationWebMar 17, 2024 · Gu J, Yin Z, Zhang J and Wang C (2024) Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension, International Journal of Cardiology, 10.1016/j.ijcard.2024.11.087, 306, (140-145), Online publication date: 1-May … phil nicholas mcgrathWebThe REACH-HFpEF pilot trial was a single-centre study with the aim of assessing the feasibility of under-taking a multicentre randomised trial to assess the clin-ical … philnic holdingsWebMar 22, 2024 · Methods: This was a post hoc analysis of the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) trial. Enrolled patients had chronic HF with left ventricular ejection fraction >40% and New York Heart Association (NYHA) class II-IV symptoms with an elevated B-type … phil nicholas